The European Medicines Agency is looking to foster the uptake of organ-on-chip (OoC) models and other microphysiological systems (MPS) in drug development and regulatory submissions, according to its planned revision of its seven-year-old guideline on the replacement, reduction and refinement (3Rs) of animal studies.
MPS models could be more predictive of in vivo biology than the in vitro and in vivo models currently used,...






